Impact of formulary policy on thiazolidinedione (TZD) use in the ontario drug benefit (ODB) program

The ODB formulary policy is very restrictive for TZD use, limiting reimbursement for second line use that must be documented in an individualized request from the prescribing physician. This study was designed to determine if patients receiving the drug met the required reimbursement criteria and whether the policy resulted in preventing appropriate patients from receiving a TZD. ODB eligible type 2 DM patients using an oral hypoglycaemic drug …